Ashling Wahner

Komal Jhaveri, MD, FACP, discusses the role of CDK4/6 inhibitors for patients with hormone receptor–positive disease and how oral SERD use is changing.

T-DXd in HER2+ Early Breast Cancer: Highlights In the neoadjuvant DESTINY-Breast11 trial, T-DXd followed by THP significantly improved pCR

Frontline Sacituzumab Govitecan and Dato-DXd: Expert Insights Both ADCs represent some of the first targeted therapies made available in the frontline for TNBC.

The phase 3 DAWN-303 trial is evaluating the oral KRAS G12D inhibitor INCB161734 in previously untreated, KRAS G12D–mutated metastatic PDAC.

Charles E. Geyer, MD, discusses data from the DESTINY-Breast05 safety analysis evaluating ILD and radiation pneumonitis outcomes in HER2+ breast cancer.

The MAPKeeper-301 trial is evaluating frontline atebimetinib plus chemotherapy vs standard chemotherapy in metastatic pancreatic ductal adenocarcinoma.

The ASPEN-09-03 trial is evaluating evorpacept plus trastuzumab and chemotherapy in previously treated HER2-positive metastatic breast cancer.

Brain cancer experts explain the current wave of surgical advances and advocate for team-based, multidisciplinary strategies to individualize patient care.

Key Takeaways Accelerated approval covers HR-positive/HER2-negative advanced disease with acquired ESR1 mutation on prior aromatase inhibitor plus CDK4/6 inhibition, requiring identification by an FDA-approved companion diagnostic test. Clinical evidence derives from switching to oral camizestrant plus continued CDK4/6 inhibition versus maintaining aromatase inhibitor plus CDK4/6 inhibitor, demonstrating median PFS improvement (16.0 vs 9.2 months). The regimen positions camizestrant as an ESR1-resistance–directed endocrine backbone while preserving CDK4/6 blockade, aligning with a targeted approach to endocrine escape in metastatic disease. SHOW MORE